Renalytix CMO, Michael Donovan, shares lessons learned moving from oncology to nephrology, and why early risk prediction could change how diabetic kidney disease is managed in primary care
![Signals From [Space]](https://substackcdn.com/image/fetch/$s_!IXc-!,w_80,h_80,c_fill,f_webp,q_auto:good,fl_progressive:steep,g_auto/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9f7142a0-6602-495d-ab65-0e4c98cc67d4_450x450.png)
![Signals From [Space]](https://substackcdn.com/image/fetch/$s_!lBsj!,e_trim:10:white/e_trim:10:transparent/h_72,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0e0f61bc-e3f5-4f03-9c6e-5ca5da1fa095_1848x352.png)
Predicting Kidney Disease Progression with…
Renalytix CMO, Michael Donovan, shares lessons learned moving from oncology to nephrology, and why early risk prediction could change how diabetic kidney disease is managed in primary care